ライフサイエンスコーパス: BPIV3

1 originated from bovine parainfluenzavirus 3 (bPIV3).

2 ine using bovine parainfluenza virus type 3 (bPIV3).

3 ouped into two subgenotypes of genotype A of bPIV3.

4 extensive host range sequence differences of BPIV3.

5 and 10(5) (n=64) or 10(6) (n=62) TCID(50) of bPIV3.

6 nge restriction and attenuation phenotype of BPIV3.

7 albeit not as severely as was observed for r-bPIV3.

8 level intermediate between that of HPIV3 and BPIV3.

9 te the attenuation phenotypes observed for r-bPIV3 and bovine/human PIV3, both of these viruses prote

10 antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine preven

11 ibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured.

12 vealed that these swine PIV3 are variants of bPIV3 and were possibly transferred from cattle to pigs

13 m antibodies than did monkeys immunized with BPIV3 and were protected from challenge with wild-type H

14 cumulative vaccine infectivity (isolation of bPIV3 and/or bPIV3 seroconversion) after dose 3 was simi

15 s, indicating that the glycoprotein genes of BPIV3 are major determinants of its host range restricti

16 trains of bovine parainfluenza virus type 3 (BPIV3) are restricted in their replication in rhesus mon

17 rovided by the host range restriction of the BPIV3 backbone in primates.

18 and the reciprocal recombinant consisting of BPIV3 bearing the HPIV3 F and HN genes (rBPIV3-F(H)HN(H)

19 for the host range attenuation phenotype of BPIV3 by exchanging each open reading frame (ORF) of a r

20 In order to test whether r-bPIV3 could serve as a vector, the fusion and hemaggluti

21 r-bPIV3 displayed a temperature-sensitive phenotype for gr

22 HPIV3 bearing the BPIV3 F and HN genes was restricted in replication in rh

23 arainfluenza type 3 virus (HPIV3) containing BPIV3 F and HN glycoprotein genes in place of its own an

24 e (TM) domains (TMCT) with counterparts from BPIV3 F, with or without pre-F stabilization.

25 the host range restriction of replication of BPIV3 for primates are polygenic, with the major determi

26 t contribution to the overall attenuation of BPIV3 for rhesus monkeys.

27 (HN) proteins from an otherwise bovine PIV3 (bPIV3) genome was employed as a vector for RSV antigen e

28 for development of pediatric vaccines since bPIV3 had already been evaluated in clinical studies in

29 ty, attenuation, and immunogenicity of these BPIV3/HPIV3 chimeras suggest that the modified Jennerian

30 nation are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI ass

31 n of the genetic basis of the attenuation of BPIV3 in primates, we produced viable chimeric HPIV3 rec

32 determinant of the host range restriction of BPIV3 in primates.

33 ein substitution on replication of HPIV3 and BPIV3 in the upper and lower respiratory tract of rhesus

34 bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine HN and F protective antigens a

35 ys than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated fr

36 on that the nucleoprotein coding sequence of BPIV3 is a determinant of its attenuation for primates.

37 BPIV3 is also restricted in replication in human infants

38 strain of bovine parainfluenza virus type 3 (BPIV3) is 100- to 1,000-fold restricted in replication i

39 Bovine parainfluenza virus type 3 (bPIV3) is being evaluated as an intranasal vaccine for p

40 of 51 participants in the vaccine groups had bPIV3 isolated after dose 4.

41 ein (N) open reading frame (ORF) from either BPIV3 Ka or SF in place of the HPIV3 N ORF.

42 tracts of monkeys, whereas those bearing the BPIV3 M or L ORF or the F and HN genes were only moderat

43 Recombinant chimeric HPIV3s bearing the BPIV3 N or P ORF were highly attenuated in the upper and

44 This identified the BPIV3 N protein as a determinant of the host range restr

45 us monkeys to a level similar to that of its BPIV3 parent virus, indicating that the glycoprotein gen

46 iters comparable to those of their HPIV3 and BPIV3 parents in LLC-MK2 monkey kidney and Madin-Darby b

47 clone of bPIV3 was assembled and recombinant bPIV3 (r-bPIV3) was rescued.

48 Furthermore, it shows that BPIV3 sequences outside the F and HN region also contrib

49 ccine infectivity (isolation of bPIV3 and/or bPIV3 seroconversion) after dose 3 was similar in the 2

50 genes of bovine parainfluenza virus type 3 (BPIV3) to its restricted replication in the respiratory

51 results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the

52 ponses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants.

53 In young infants, the bPIV3 vaccine appears to be infectious, attenuated, immu

54 omparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developin

55 To test the potential of the bPIV3 vaccine strain as a vector, an infectious DNA clon

56 Multiple doses of bPIV3 vaccine were well tolerated and immunogenic in you

57 ian tissue culture infective dose (TCID(50)) bPIV3 vaccine, 1x10(6) TCID(50) bPIV3 vaccine, or placeb

58 e (TCID(50)) bPIV3 vaccine, 1x10(6) TCID(50) bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months o

59 rain as a vector, an infectious DNA clone of bPIV3 was assembled and recombinant bPIV3 (r-bPIV3) was

60 Isolation of bPIV3 was common after dose 1, dose 2, or dose 3, but on

61 In summary, bPIV3 was shown to function as a virus vector that may b

62 bPIV3 was assembled and recombinant bPIV3 (r-bPIV3) was rescued.

63 ion and hemagglutinin-neuraminidase genes of bPIV3 were replaced with those of hPIV3.

64 The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exceptio

65 cterized host range attenuation phenotype of BPIV3, which appears to be appropriate for immunization

66 wild-type HPIV3 with the analogous ORF from BPIV3, with the caveats that the multiple ORFs of the P